Abstract
Selexipag (Uptravi((R))) is an orally active, first-in-class, selective prostacyclin IP receptor agonist. Selexipag was approved recently in the EU fo......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
